Drug therapies for the treatment of melanoma are advancing, and many now play a role for the treatment of earlier stage disease, according to new research.
2024
FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma
This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.
AMLo Biosciences Gets UKCA Mark for Melanoma Biomarker Test
NEW YORK — AMLo Biosciences said Tuesday that it has received UK Conformity Assessed (UKCA) marking for its AMBLor test for identifying early-stage melanomas at low risk of progression.
Immunotherapy Combination Elicit Waves of Response in Advanced Melanoma
A new algorithm has found that combining immune checkpoint inhibitors bolsters immune response among some patients with advanced melanoma.